Merck, Lilly Vow To Press On With CETP, Despite Dalcetrapib Disaster
This article was originally published in The Pink Sheet Daily
Early termination of a large outcomes study of Roche’s CETP inhibitor dalcetrapib raises doubts about others in the class. Some analysts speculate that Eli Lilly may opt not to continue with its evacetrapib, but the company says it remains committed.
You may also be interested in...
NewAmsterdam Is Behind Another Try At CETP Inhibition, With Menarini’s Help
Years after failures by Merck, Lilly, Pfizer and Roche, NewAmsterdam hopes to bring a CETP inhibitor to market to lower cholesterol, and signs on with Menarini to lead commercial efforts in Europe.
Deal Watch: NewAmsterdam To Take On Amgen’s Stalled CETP Inhibitor
New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.
Merck Calls It Quits On Anacetrapib
Despite success in REVEAL outcomes trial, Merck will not submit the for the cholesteryl ester transfer protein (CETP) inhibitor for regulatory approval.